research collaboration
Novo Nordisk Signs $812M Deal with Deep Apple to Develop Non-Incretin Obesity Drugs
Novo Nordisk; Deep Apple Therapeutics; obesity; non-incretin; GPCR; cardiometabolic disease; small molecules; research collaboration; deal; drug discovery
Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases
Novo Nordisk, Photys Therapeutics, Cardiometabolic diseases, Proximity-based therapeutics, PHICS technology, Research collaboration